Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC.
10.3779/j.issn.1009-3419.2023.102.40
- Author:
Huaiyong WANG
1
;
Yun HAN
1
Author Information
1. Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang 110000, China.
- Publication Type:Journal Article
- Keywords:
Event-free survival;
Immunotherapy;
Lung neoplasms;
Neoadjuvant therapy;
Surgery;
Treatment cycle
- MeSH:
Humans;
Neoadjuvant Therapy;
Carcinoma, Non-Small-Cell Lung/surgery*;
Retrospective Studies;
Lung Neoplasms/surgery*;
Immunotherapy
- From:
Chinese Journal of Lung Cancer
2023;26(11):822-832
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:For resectable non-small cell lung cancer (NSCLC), the CheckMate-816 study demonstrated that neoadjuvant chemoimmunotherapy increased the rate of complete pathologic response (pCR) by 21.8% compared with chemotherapy alone and resulted in a significant benefit in event-free survival (EFS). This study aimed to investigate the safety and feasibility of this approach in the real world.
METHODS:Clinical data from patients with NSCLC who underwent surgery after neoadjuvant chemoimmunotherapy or chemotherapy alone in two centers were analyzed retrospectively, and subgroup analyses were performed for the chemoimmunotherapy group according to treatment cycle. The primary study endpoints were EFS and major pathologic response (MPR), and the secondary study endpoints were pCR, overall survival (OS), treatment-related adverse events (TRAEs), and surgery-related metrics.
RESULTS:As of April 2023, 89 patients had been enrolled, including 54 in the chemoimmunotherapy group and 35 in the chemotherapy alone group. MPR was achieved in 31 (57.4%) and 5 (14.3%) patients in the chemoimmunotherapy group and chemotherapy alone group, respectively (OR=8.09, 95%CI: 2.72-24.04, P<0.001); pCR was achieved in 25 (46.3%) patients in the chemoimmunotherapy group and no patient in the chemotherapy alone group (P<0.001). The median follow-up time was 22.1 months. At 24 months, the EFS rates of the chemoimmunotherapy group and the chemotherapy alone group were 77.0% and 56.7%, respectively (P=0.026), and the OS rates were 87.1% and 67.7%, respectively (P=0.020). In the neoadjuvant chemoimmunotherapy group, there was no significant difference between the 1-2 cycles and 3-5 cycles groups in terms of operation time, intraoperative blood loss, and postoperative complications.
CONCLUSIONS:Neoadjuvant chemoimmunotherapy was more effective than chemotherapy alone and did not increase the risk associated with surgery. An increase in the number of cycles of neoadjuvant chemoimmunotherapy had no significant effect on the difficulty of surgery.
